ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

American Society of Echocardiography Invests in Joint Research Initiative to Help Patients Suffering from Wide-Reaching Form of Heart Failure

Durham, NC, Sept. 29, 2022 (GLOBE NEWSWIRE) -- The American Society of Echocardiography (ASE) is targeting its research funding over the next five years to help solve some of the mysteries around the early detection of a common form of heart failure. ASE is one of the key partner organizations in a joint research initiative that aims to identify more precise treatment strategies for patients suffering from heart failure with preserved ejection fraction (HFpEF).

The Accelerating Medicines Partnership® Heart Failure (AMP® HF) Program will utilize more than $37 million in funding from private and public collaborators—which includes ASE—to better diagnose and develop treatment options for HFpEF and improve the outlook for millions of patients around the world. The Foundation for the National Institutes of Health (FNIH) and the National Heart Lung and Blood Institute (NHLBI) at the National Institutes of Health (NIH) will facilitate the program over the next five years.

“One of ASE’s current strategic goals is to focus our efforts where they are most needed,” says Stephen H. Little, MD, FASE, FRCPC, FACC, ASE’s 2022-2023 Board of Directors President. “The Society is proud to support research projects like AMP HF because of the great promise the findings can have in advancing the field of cardiovascular ultrasound and improving patient care.”

HFpEF is a common form of heart failure that is difficult to detect. It is often deadly, with a five-year survival rate of just 35-40%. In addition to a high risk for mortality, patients with HFpEF live with declining quality of life and poor capacity to perform tasks of daily living.

The AMP HF Program will advance the understanding of HFpEF using two complementary and integrated research components: analyzing existing HFpEF datasets, sourced from public and private sector funded studies, and initiating a new clinical trial to confirm retrospective findings in an observational cohort with a goal to develop a framework for new precision treatments.

“Echocardiography is a specialty that already plays a significant role in diagnosing heart conditions, and we look forward to continuing to learn how echocardiographic screenings can be used in understanding the many still unanswered questions about HFpEF,” says Judy Hung, MD, FASE, who is a cardiologist with Massachusetts General Hospital and an ASE past president.

“Research shapes the future of medicine, and ASE is honored to be among some of the largest and most innovative biomedical partners contributing to this important initiative,” Dr. Hung added.

ASE’s charitable arm, the ASE Foundation, provides support for initiatives that are not funded by membership dues—such as training scholarships and scientific research. In the last 25 years, the Society and its Foundation have contributed more than $7.3 million to cardiovascular health research.

About American Society of Echocardiography
The American Society of Echocardiography (ASE) is the Society for Cardiovascular Ultrasound Professionals™. ASE is the largest global organization for cardiovascular ultrasound imaging serving physicians, sonographers, nurses, veterinarians, and scientists and as such is the leader and advocate, setting practice standards and guidelines for the field. The Society is committed to advancing cardiovascular ultrasound to improve lives. For more information, visit the ASE website ASEcho.org or social media pages on Facebook, Twitter or LinkedIn.

About the Foundation for the National Institutes of Health: The Foundation for the National Institutes of Health (FNIH) creates and manages alliances with public and private institutions in support of the mission of the NIH. FNIH works with its partners to accelerate biomedical research and strategies against diseases and health concerns in the United States and across the globe. The FNIH organizes and administers research projects; supports education and training of new researchers; organizes educational events and symposia; and administers a series of funds supporting a wide range of health issues—all efforts focused on areas of unmet need, paving the way toward better patient experiences and outcomes. Established by Congress in 1990, the FNIH is a not-for-profit 501(c)(3) charitable organization. For additional information about the FNIH, please visit https://fnih.org.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit https://www.nih.gov/.

###

Attachment


Angie Porter
American Society of Echocardiography
9192977152
aporter@asecho.org

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.56
+0.02 (0.01%)
AAPL  274.61
+0.50 (0.18%)
AMD  209.17
+1.59 (0.77%)
BAC  54.81
-0.52 (-0.94%)
GOOG  307.73
-1.59 (-0.51%)
META  657.15
+9.64 (1.49%)
MSFT  476.39
+1.57 (0.33%)
NVDA  177.72
+1.43 (0.81%)
ORCL  188.65
+3.73 (2.02%)
TSLA  489.88
+14.57 (3.07%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.